Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma

• Published in: Annals of hematology 2024-10, Vol.103 (10), p.3839-3853
• Main Authors: Duan, Hongpeng, Jiang, Qiuhui, Liu, Long, Deng, Manman, Lai, Qian, Jiang, Yuelong, Li, Zhifeng, Xu, Bing, Lin, Zhijuan
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Benzylamines; Cohort analysis; Cyclams - pharmacology; Cyclams - therapeutic use; Hematology; Hematopoietic Stem Cell Mobilization - methods; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells - drug effects; Humans; Lenalidomide - administration & dosage; Lenalidomide - therapeutic use; Medicine; Medicine & Public Health; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - therapy; Oncology; Review; Stem cells
• ISSN: 0939-5555; 1432-0584; 1432-0584
• DOI: 10.1007/s00277-024-05683-2

Background The roles of Lenalidomide (Len) and Daratumumab (Dara) in multiple myeloma treatment are well-established, yet their influences on hematopoietic stem cell harvesting and reconstitution remain disputed. Methods We conducted a systematic database review to identify cohort studies or RCTs evaluating the effect of the use of Len or Dara on hematopoietic stem cell collection and peripheral blood count recovery in multiple myeloma patients. Effects on hematopoietic collection or reconstitution were estimated by comparing standardized mean differences (SMD) and mean differences (MD), or median differences. Results Eighteen relevant studies were identified, summarizing mobilization results. For Len, data from 13 studies were summarized, including total CD34+ cell yield, collection failure rate, and time to neutrophil and platelet engraftment. Results indicated that Len exposure led to decreased stem cell collection [SMD=-0.23, 95% CI (-0.34, -0.12)]. However, collection failure (